Enhancement of Lymphokine-Activated Killer Cell Cytotoxicity Implicated in the Increased Expression of Surface Adhesion Molecules on Tumor Cells Treated with Anticancer Agents-Reference-Cited by-同舟云学术

Enhancement of Lymphokine-Activated Killer Cell Cytotoxicity Implicated in the Increased Expression of Surface Adhesion Molecules on Tumor Cells Treated with Anticancer Agents

Published:1996-01 Issue:5 Volume:14 Page:427-434
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Ishihata Ryoichi,Ejiria Yutaka,Okuboa Mitsuo,Oharaa Morihiro,Kasukawaa Reiji

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/07357909609018900

Reference30 articles.

1. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

2. Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

3. A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

4. Immunoregulation by Cancer Chemotherapeutic Agents

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases;Medicinal Research Reviews;2002-02-08

2. Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-κB independent pathway;British Journal of Cancer;1999-05-07

3. Lymphokine-Activated Killer (LAK)-Mediated Lysis of Sequentially Isolated Ovarian Cancer Cell Lines;American Journal of Reproductive Immunology;1997-12

4. Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells;International Journal of Cancer;1997-11-04